Latest Innovation News

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Noumi Limited reported modest revenue growth and a significant rise in adjusted EBITDA for FY25, driven by its Milklab brand’s strong performance and a continued turnaround in its Dairy & Nutritionals segment. The company also resolved all legacy legal issues, positioning itself for future growth.

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Veris Limited has reported a significant turnaround in FY25, posting a $2 million profit before tax on $97.2 million revenue, driven by growth in digital and spatial advisory services and strategic acquisitions.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Veris Limited has reported a significant financial turnaround for the year ended June 2025, returning to profitability and boosting earnings, while strategically acquiring Spatial Vision to broaden its geospatial services across Australia.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.

Pointerra Limited reported a strong FY25 with revenue up 45% to A$11 million and a significant reduction in net loss by 68%, driven by scalable SaaS growth and key US contract wins.

Cedar Woods Properties has reported a robust 19% rise in net profit for FY25, surpassing guidance with strong presales and strategic partnerships setting the stage for continued growth.

Restaurant Brands New Zealand Limited reported record group store sales of NZ$703.2 million for the half year ended 30 June 2025, but rising costs pressured profits and margins across key markets.